Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Department of Anesthesiology and Intensive Care, Uniklinikum Jena, Jena, Germany.
JAMA. 2020 Apr 21;323(15):1478-1487. doi: 10.1001/jama.2020.2717.
Infection is frequent among patients in the intensive care unit (ICU). Contemporary information about the types of infections, causative pathogens, and outcomes can aid the development of policies for prevention, diagnosis, treatment, and resource allocation and may assist in the design of interventional studies.
To provide information about the prevalence and outcomes of infection and the available resources in ICUs worldwide.
DESIGN, SETTING, AND PARTICIPANTS: Observational 24-hour point prevalence study with longitudinal follow-up at 1150 centers in 88 countries. All adult patients (aged ≥18 years) treated at a participating ICU during a 24-hour period commencing at 08:00 on September 13, 2017, were included. The final follow-up date was November 13, 2017.
Infection diagnosis and receipt of antibiotics.
Prevalence of infection and antibiotic exposure (cross-sectional design) and all-cause in-hospital mortality (longitudinal design).
Among 15 202 included patients (mean age, 61.1 years [SD, 17.3 years]; 9181 were men [60.4%]), infection data were available for 15 165 (99.8%); 8135 (54%) had suspected or proven infection, including 1760 (22%) with ICU-acquired infection. A total of 10 640 patients (70%) received at least 1 antibiotic. The proportion of patients with suspected or proven infection ranged from 43% (141/328) in Australasia to 60% (1892/3150) in Asia and the Middle East. Among the 8135 patients with suspected or proven infection, 5259 (65%) had at least 1 positive microbiological culture; gram-negative microorganisms were identified in 67% of these patients (n = 3540), gram-positive microorganisms in 37% (n = 1946), and fungal microorganisms in 16% (n = 864). The in-hospital mortality rate was 30% (2404/7936) in patients with suspected or proven infection. In a multilevel analysis, ICU-acquired infection was independently associated with higher risk of mortality compared with community-acquired infection (odds ratio [OR], 1.32 [95% CI, 1.10-1.60]; P = .003). Among antibiotic-resistant microorganisms, infection with vancomycin-resistant Enterococcus (OR, 2.41 [95% CI, 1.43-4.06]; P = .001), Klebsiella resistant to β-lactam antibiotics, including third-generation cephalosporins and carbapenems (OR, 1.29 [95% CI, 1.02-1.63]; P = .03), or carbapenem-resistant Acinetobacter species (OR, 1.40 [95% CI, 1.08-1.81]; P = .01) was independently associated with a higher risk of death vs infection with another microorganism.
In a worldwide sample of patients admitted to ICUs in September 2017, the prevalence of suspected or proven infection was high, with a substantial risk of in-hospital mortality.
感染在重症监护病房(ICU)的患者中很常见。有关感染类型、病原体和结果的最新信息可以帮助制定预防、诊断、治疗和资源分配的政策,并可能有助于设计干预性研究。
提供全球 ICU 中感染的流行率和结果以及可用资源的信息。
设计、设置和参与者:在 88 个国家的 1150 个中心进行的观察性 24 小时点患病率研究,具有 1150 个中心的纵向随访。在 2017 年 9 月 13 日 08:00 开始的 24 小时内,在参与的 ICU 中接受治疗的所有成年患者(年龄≥18 岁)均包括在内。最终随访日期为 2017 年 11 月 13 日。
感染诊断和抗生素使用。
感染和抗生素使用的患病率(横断面设计)以及全因院内死亡率(纵向设计)。
在纳入的 15202 名患者中(平均年龄为 61.1 岁[标准差,17.3 岁];9181 名为男性[60.4%]),15165 名患者(99.8%)有感染数据;8135 名(54%)患者有疑似或确诊感染,其中 1760 名(22%)患者有 ICU 获得性感染。共有 10640 名患者(70%)至少接受了 1 种抗生素。疑似或确诊感染患者的比例范围从 43%(141/328)的澳大拉西亚到亚洲和中东的 60%(1892/3150)。在 8135 名疑似或确诊感染患者中,5259 名(65%)至少有 1 次阳性微生物培养结果;在这些患者中,67%(n=3540)为革兰氏阴性微生物,37%(n=1946)为革兰氏阳性微生物,16%(n=864)为真菌微生物。疑似或确诊感染患者的院内死亡率为 30%(2404/7936)。在多水平分析中,与社区获得性感染相比,ICU 获得性感染与更高的死亡率风险独立相关(优势比[OR],1.32[95%CI,1.10-1.60];P=0.003)。在抗生素耐药微生物中,与感染另一种微生物相比,耐万古霉素肠球菌(OR,2.41[95%CI,1.43-4.06];P=0.001)、耐β-内酰胺类抗生素(包括第三代头孢菌素和碳青霉烯类抗生素)的克雷伯菌(OR,1.29[95%CI,1.02-1.63];P=0.03)或耐碳青霉烯类不动杆菌属物种(OR,1.40[95%CI,1.08-1.81];P=0.01)与死亡风险增加独立相关。
在 2017 年 9 月收治的 ICU 患者的全球样本中,疑似或确诊感染的流行率很高,院内死亡率风险很大。